➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Mallinckrodt
Johnson and Johnson
Baxter
Colorcon

Last Updated: October 25, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,361,500

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,361,500 protect, and when does it expire?

Patent 8,361,500 protects VARUBI and is included in one NDA.

This patent has sixteen patent family members in ten countries.

Summary for Patent: 8,361,500
Title:Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaz- a-spiro[4.5]decan-2-one salts and tablets made therefrom
Abstract: Pharmaceutical formulations containing a salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-ph- enyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, which are suitable for forming into a tablet dosage form, as well as tablet dosage forms are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.
Inventor(s): Qiu; Zhihui (Bridgewater, NJ), Cho; Wing-Kee Philip (Princeton, NJ), Zhao; Na (Belle Mead, NJ), Wong; Victor Ming-she (Berkeley Heights, NJ)
Assignee: Opko Health, Inc. (Miami, FL)
Application Number:12/531,966
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Process;

Drugs Protected by US Patent 8,361,500

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Tersera Theraps Llc VARUBI rolapitant hydrochloride TABLET;ORAL 206500-001 Sep 1, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,361,500

PCT Information
PCT FiledMarch 20, 2008PCT Application Number:PCT/US2008/003653
PCT Publication Date:October 02, 2008PCT Publication Number: WO2008/118331

International Family Members for US Patent 8,361,500

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 065802   Start Trial
Canada 2681465   Start Trial
Chile 2008000819   Start Trial
European Patent Office 2136793   Start Trial
Spain 2406934   Start Trial
Japan 2010522173   Start Trial
Japan 2013216694   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Medtronic
Mallinckrodt
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.